European Cannabis Insights 2026 Whitepaper

0 items - £0.00 0

European Cannabis Insights 2026 Whitepaper

The European Cannabis Insights 2026 Whitepaper captures the presentations, debates and expert insights from the European Cannabis Insights Summit, held in Berlin on 10 June 2026 — the first industry report from Business of Cannabis, powered by Prohibition Partners' market data.

Convening the leading voices in Europe's largest and most dynamic cannabis market, the report sets out a clear thesis: the European medical cannabis market has established its foundations, and the winners of the next phase will be decided less by regulatory outcomes than by the operational and structural choices operators make in the next two to three years.

Germany's market matures: worth ≈€1.15 billion in 2026 and projected to reach €1.4–1.6 billion by 2030 — with growth now driven by volume rather than price, and imports covering ~99% of supply.
The import surge: German medical cannabis imports grew 176% in 2025 to 201 tonnes, while pharmacy flower prices fell 46% to €4.52/g — the price-compression fault line now threatening EU-GMP cultivators.
The post-CanG demand story: prescription volumes up 3,300% since reclassification, Bloomwell's patient base 29× larger, the median patient age down from 36 to 31 — and eastern Germany closing its access gap at 123× pre-CanG patient penetration.
Two markets, one industry: self-pay patients generate ~75% of German market value despite 90% of Germans being GKV-eligible — and physicians name fear of financial clawback (76.3%), not clinical doubt, as the reason they won't prescribe.
Poland's shock and recovery: a 2024 telemedicine ban cut prescriptions by 57% in a single month; hybrid clinics restored volume while prices fell 28% — the clearest case study of regulatory risk in Europe.
The UK and France: the UK is the fastest-growing market behind Germany (£302–389 million, >140,000 patients); France moves from pilot to a permanent framework expected by 2027, forecast to exceed €170 million by 2031.
From pilot to policy: Switzerland's adult-use trials halved participants' illicit-market sourcing, with 66% no longer buying illicit cannabis at all.
The July 2026 rule change: the report includes analysis of the GKV-Beitragsstabilisierungsgesetz, which removed medical cannabis flower from statutory reimbursement — passed after the summit and reshaping the reimbursed market.

Contents

Foreword — Ben Stevens, Editor, Business of Cannabis
Executive Summary
European Market Outlook — key market metrics across Germany, the UK, Poland and France; country deep-dives; risks & opportunities
Supply Under Pressure — price compression, Canadian dominance and the quality fault line
The Post-CanG German Market — demand, behaviour and what the data shows
Two Markets, One Industry — patient profiles across the GKV and self-pay divide
From Pilot to Policy — what Europe's adult-use trials are teaching regulators
Acronyms

European Cannabis Insights 2026 Whitepaper

Germany's market matures: worth ≈€1.15 billion in 2026 and projected to reach €1.4–1.6 billion by 2030 — with growth now driven by volume rather than price, and imports covering ~99% of supply.
The import surge: German medical cannabis imports grew 176% in 2025 to 201 tonnes, while pharmacy flower prices fell 46% to €4.52/g — the price-compression fault line now threatening EU-GMP cultivators.
The post-CanG demand story: prescription volumes up 3,300% since reclassification, Bloomwell's patient base 29× larger, the median patient age down from 36 to 31 — and eastern Germany closing its access gap at 123× pre-CanG patient penetration.
Two markets, one industry: self-pay patients generate ~75% of German market value despite 90% of Germans being GKV-eligible — and physicians name fear of financial clawback (76.3%), not clinical doubt, as the reason they won't prescribe.
Poland's shock and recovery: a 2024 telemedicine ban cut prescriptions by 57% in a single month; hybrid clinics restored volume while prices fell 28% — the clearest case study of regulatory risk in Europe.
The UK and France: the UK is the fastest-growing market behind Germany (£302–389 million, >140,000 patients); France moves from pilot to a permanent framework expected by 2027, forecast to exceed €170 million by 2031.
From pilot to policy: Switzerland's adult-use trials halved participants' illicit-market sourcing, with 66% no longer buying illicit cannabis at all.
The July 2026 rule change: the report includes analysis of the GKV-Beitragsstabilisierungsgesetz, which removed medical cannabis flower from statutory reimbursement — passed after the summit and reshaping the reimbursed market.

Add To Cart

Overview

On 10 June 2026, Business of Cannabis and CB Club convened the European Cannabis Insights Summit in Berlin, bringing together the executives, clinicians and policy specialists shaping Europe's largest cannabis market. This whitepaper — the third industry report from Business of Cannabis, powered by Prohibition Partners — captures the summit's presentations, debates and data, alongside Prohibition Partners' underlying market intelligence.

The report examines four European markets at four different stages of the same cycle: Germany maturing, the United Kingdom growing, Poland recovering and France preparing to open. Germany anchors the analysis: a ≈€1.15 billion market in 2026, projected to reach €1.4–1.6 billion by 2030, where a 176% import surge and a 46% fall in pharmacy prices are forcing structural questions about supply, quality enforcement and margin survival.

Drawing on longitudinal patient data from Bloomwell, physician reimbursement data from Copeia, supply-chain economics from alephSana and Cannamedical, regulatory analysis from EUMCA and CannaVigia, clinical channel insight from CKM Group and Cannaleo Digital, and lessons from Sanity Group's Swiss adult-use pilot, the whitepaper maps demand, behaviour and policy across the continent — including the July 2026 removal of cannabis flower from German statutory reimbursement, which came into effect after the summit and is analysed in the report.

For operators, investors and policymakers, the conclusion is direct: Europe's medical cannabis market has established its foundations. What gets built on top of them will be decided in the next two to three years.

Maturity, not regulation, now decides the winners. Across Germany, the UK, Poland and France, regulatory and pricing pressure consistently lag market maturity — and scale, vertical integration and own-brand positioning emerge as the strongest hedges against margin compression as these markets grow.
Price compression has become existential for compliant supply. With pharmacy prices at €4.52/g and Canadian-origin product accounting for an effective ~74% share of German imports, EU-GMP cultivation is no longer economically viable at current price levels — and stricter enforcement of quality standards would remove up to 80% of current supply from the market.
Germany is now two distinct markets. The self-pay patient is typically a 31-year-old male ordering mid-potency flower every 26 days; the reimbursed patient is majority female, peaks at age 56–60, is prescribed extracts — and the fastest-growing GKV cohort is aged 75 and above. Serving both requires different products, channels and clinical pathways.
Telemedicine restriction is the single largest quantified risk. Prohibition Partners modelled a German telemedicine restriction as a ~€600 million market decline, based on Poland's experience of a 57% overnight fall in prescriptions — context for a bill the summit assessed as stalled, but not gone.
Adult-use pilots are building the evidentiary case regulators asked for. Swiss trial participants halved their illicit-market sourcing within two years, with measurable harm-reduction outcomes — while every German pilot application to date has been rejected for lack of legal basis.
The reimbursement ground has already shifted. After the summit, the Bundestag removed cannabis flower from GKV reimbursement entirely, with extracts and dronabinol now subject to a mandatory six-month therapeutic trial of an approved finished medicine — a change the report documents alongside the patient-association backlash.

As Trusted By

Insights

on the global cannabis industry

International Cannabis Weekly newsletter brings you the most important developments, news and informed commentary on the global cannabis industry. Join our community of 80,000+ subscribers.

European Cannabis Insights 2026 Whitepaper

European Cannabis Insights 2026 Whitepaper

As Trusted By

Insights

on the global cannabis industry

Market Briefing Request

In Depth Analysis Session Request

Data Access Request